The myeloprotective effect of trilaciclib in the treatment of small cell lung cancer
Objective:To explore the myeloprotective effects of trilaciclib in the chemotherapy of small cell lung cancer(SCLC)so as to provide references for safe medication.Methods:A case of extensive-stage SCLC patient experienced gradeⅣ bone marrow suppression after first cycle of etoposide and carboplatin chemotherapy plus durvalumab monoclonal antibody.Clinical pharmacists participated in the patient's drug treatment process and provided pharmaceutical service for healthcare professionals and patients.Results:During the later stages of chemotherapy plus immunotherapy,the patient was administered trilaciclib 4 hours before using anti-tumor drugs and there was no significant decrease in white blood cells count,neutrophils count,hemoglobin level,and platelets count subsequently.Conclusion:For SCLC patients who experienced a significant bone marrow suppression after chemotherapy,trilaciclib can be administered when the original regimen is reapplied.However,close attention should be paid to potential adverse reactions such as phlebitis and thrombosis caused by trilaciclib.
small cell lung canceretoposidecarboplatintrilaciclibmyelosuppression
万方数据
维普
